Chromosomal translocations involving the MLL gene: Molecular mechanisms

DNA Repair

Volumn 5, Issue 9-10, 2006, Pages 1265-1272

  Aplan, Peter D ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Chromosomal translocation; DNA topoisomerase II; Infant leukemia; MLL; Non homologous end joining

Indexed keywords

ANTHRACYCLINE; BCR ABL PROTEIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE INHIBITOR; EPIPODOPHYLLOTOXIN; ETOPOSIDE; HOX PROTEIN; MIXED LINEAGE LEUKEMIA PROTEIN; NUCLEOPORIN 98; PROMYELOCYTIC LEUKEMIA PROTEIN; RECOMBINASE; TRANSCRIPTION FACTOR RUNX1;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ALU SEQUENCE; APOPTOSIS; CANCER CHEMOTHERAPY; CELL CYCLE REGULATION; CELL DIFFERENTIATION; CELL PROLIFERATION; CHROMOSOME REARRANGEMENT; CHROMOSOME TRANSLOCATION; DNA STRAND BREAKAGE; FUSION GENE; GENE CLUSTER; GENE DELETION; GENE EXPRESSION; GENE INSERTION; GENE LOCUS; GENE MAPPING; GENE MUTATION; GENETIC RECOMBINATION; HEMATOLOGIC MALIGNANCY; HUMAN; LEUKEMIA; MALIGNANT TRANSFORMATION; MOLECULAR MECHANICS; NONHUMAN; PRIORITY JOURNAL; REVIEW;

BASE SEQUENCE; CHROMATIN; DNA TOPOISOMERASES, TYPE II; HUMANS; INFANT; LEUKEMIA, MYELOCYTIC, ACUTE; LEUKEMIA, MYELOID, ACUTE; MODELS, GENETIC; MOLECULAR SEQUENCE DATA; MYELOID-LYMPHOID LEUKEMIA PROTEIN; RECOMBINATION, GENETIC; TOPOISOMERASE II INHIBITORS; TRANSLOCATION, GENETIC;

EID: 33748178469     PISSN: 15687864     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dnarep.2006.05.034     Document Type: Review

References (71)

1. Rowley J.D. Chromosome translocations: dangerous liaisons revisited. Nat. Rev. Cancer 1 (2001) 245-250
2. Rabbitts T.H. Chromosomal translocation master genes, mouse models and experimental therapeutics. Oncogene 20 (2001) 5763-5777
3. Aplan P.D. Causes of oncogenic chromosomal translocation. Trends Genet. 22 (2006) 46-55
4. Chou W.C., and Dang C.V. Acute promyelocytic leukemia: recent advances in therapy and molecular basis of response to arsenic therapies. Curr. Opin. Hematol. 12 (2005) 1-6
5. Hunger S.P. Chromosomal translocations involving the E2A gene in acute lymphoblastic leukemia: clinical features and molecular pathogenesis. Blood 87 (1996) 1211-1224
6. Hunger S.P., Li S., Fall M.Z., Naumovski L., and Cleary M.L. The proto-oncogene HLF and the related basic leucine zipper protein TEF display highly similar DNA-binding and transcriptional regulatory properties. Blood 87 (1996) 4607-4617
7. Hess J.L. MLL: a histone methyltransferase disrupted in leukemia. Trends Mol. Med. 10 (2004) 500-507
8. Thirman M.J., Gill H.J., Burnett R.C., Mbangkollo D., McCabe N.R., Kobayashi H., Zieminvanderpoel S., Kaneko Y., Morgan R., Sandberg A.A., Chaganti R.S.K., Larson R.A., Lebeau M.M., Diaz M.O., and Rowley J.D. Rearrangement of the MLL gene in acute lymphoblastic and acute myeloid leukemias with 11q23 chromosomal translocations. New Engl. J. Med. 329 (1993) 909-914
9. Daser A., and Rabbitts T.H. The versatile mixed lineage leukaemia gene MLL and its many associations in leukaemogenesis. Semin. Cancer Biol. 15 (2005) 175-188
10. Eguchi M., Eguchi-Ishimae M., and Greaves M. The role of the MLL gene in infant leukemia. Int. J. Hematol. 78 (2003) 390-401
11. Rubnitz J.E., Camitta B.M., Mahmoud H., Raimondi S.C., Carroll A.J., Borowitz M.J., Shuster J.J., Link M.P., Pullen D.J., Downing J.R., Behm F.G., and Pui C.H. Childhood acute lymphoblastic leukemia with the MLL-ENL fusion and t(11;19)(q23;p13.3) translocation. J. Clin. Oncol. 17 (1999) 191-196
12. Nagayama J., Tomizawa D., Koh K., Nagatoshi Y., Hotta N., Kishimoto T., Takahashi Y., Kuno T., Sugita K., Sato T., Kato K., Ogawa A., Nakahata T., Mizutani S., Horibe K., and Ishii E. Infants with acute lymphoblastic leukemia and a germline MLL gene are highly curable with use of chemotherapy alone: results from the Japan Infant Leukemia Study Group. Blood 107 (2006) 4663-4665
13. Pedersen-Bjergaard J., Andersen M.K., and Johansson B. Balanced chromosome aberrations in leukemias following chemotherapy with DNA-topoisomerase II inhibitors. J. Clin. Oncol. 16 (1998) 1897-1898
14. Hahn W.C., and Weinberg R.A. Rules for making human tumor cells. N. Engl. J. Med. 347 (2002) 1593-1603
15. Gilliland D.G., and Tallman M.S. Focus on acute leukemias. Cancer Cell 1 (2002) 417-420
16. Greaves M. Pre-natal origins of childhood leukemia. Rev. Clin. Exp. Hematol. 7 (2003) 233-245
17. Higuchi M., O'Brien D., Kumaravelu P., Lenny N., Yeoh E.J., and Downing J.R. Expression of a conditional AML1-ETO oncogene bypasses embryonic lethality and establishes a murine model of human t(8;21) acute myeloid leukemia. Cancer Cell 1 (2002) 63-74
18. Abe R., Ryan D., Cecalupo A., Cohen H., and Sandberg A.A. Cytogenetic findings in congenital leukemia: case report and review of the literature. Cancer Genet. Cytogenet. 9 (1983) 139-144
19. Ridge S.A., Cabrera M.E., Ford A.M., Tapia S., Risueno C., Labra S., Barriga F., and Greaves M.F. Rapid intraclonal switch of lineage dominance in congenital leukaemia with a MLL gene rearrangement. Leukemia 9 (1995) 2023-2026
20. Hunger S.P., McGavran L., Meltesen L., Parker N.B., Kassenbrock C.K., and Bitter M.A. Oncogenesis in utero: fetal death due to acute myelogenous leukaemia with an MLL translocation. Br. J. Haematol. 103 (1998) 539-542
21. Greaves M.F., Maia A.T., Wiemels J.L., and Ford A.M. Leukemia in twins: lessons in natural history. Blood 102 (2003) 2321-2333
22. Adler H.T., Chinery R., Wu D.Y., Kussick S.J., Payne J.M., Fornace Jr. A.J., and Tkachuk D.C. Leukemic HRX fusion proteins inhibit GADD34-induced apoptosis and associate with the GADD34 and hSNF5/INI1 proteins. Mol. Cell. Biol. 19 (1999) 7050-7060
23. Wiederschain D., Kawai H., Gu J., Shilatifard A., and Yuan Z.M. Molecular basis of p53 functional inactivation by the leukemic protein MLL-ELL. Mol. Cell. Biol. 23 (2003) 4230-4246
24. Caslini C., Shilatifard A., Yang L., and Hess J.L. The amino terminus of the mixed lineage leukemia protein (MLL) promotes cell cycle arrest and monocytic differentiation. Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 2797-2802
25. Wiemels J.L., Pagnamenta A., Taylor G.M., Eden O.B., Alexander F.E., and Greaves M.F. A lack of a functional NAD(P)H:quinone oxidoreductase allele is selectively associated with pediatric leukemias that have MLL fusions. Cancer Res. 59 (1999) 4095-4099
26. Felix C.A., Walker A.H., Lange B.J., Williams T.M., Winick N.J., Cheung N.K., Lovett B.D., Nowell P.C., Blair I.A., and Rebbeck T.R. Association of CYP3A4 genotype with treatment-related leukemia. Proc. Natl. Acad. Sci. U.S.A. 95 (1998) 13176-13181
27. Pedersen-Bjergaard J., Pedersen M., Roulston D., and Philip P. Different genetic pathways in leukemogenesis for patients presenting with therapy-related myelodysplasia and therapy-related acute myeloid leukemia. Blood 86 (1995) 3542-3552
28. Smith M.A., McCaffrey R.P., and Karp J.E. The secondary leukemias: challenges and research directions. J. Natl. Cancer Inst. 88 (1996) 407-418
29. Haupt R., Fears T.R., Rosso P., Colella R., Loiacono G., de Terlizzi M., Mancini A., Comelli A., Indolfi P., Donfrancesco A., et al. Increased risk of secondary leukemia after single-agent treatment with etoposide for Langerhans' cell histiocytosis. Pediatr. Hematol. Oncol. 11 (1994) 499-507
30. Maraschin J., Dutrillaux B., and Aurias A. Chromosome aberrations induced by etoposide (VP-16) are not random. Int. J. Cancer 46 (1990) 808-812
31. Smith M.A., Rubinstein L., and Ungerleider R.S. Therapy-related acute myeloid leukemia following treatment with epipodophyllotoxins: estimating the risks. Med. Pediatr. Oncol. 23 (1994) 86-98 (review, 131 refs)
32. Deveney R., Chervinsky D.S., Jani-Sait S.N., Grossi M., and Aplan P.D. Insertion of MLL sequences into chromosome band 5q31 results in an MLL-AF5Q31 fusion and is a rare but recurrent abnormality associated with infant leukemia. Genes Chromosomes Cancer 37 (2003) 326-331
33. Caligiuri M.A., Strout M.P., Schichman S.A., Mrozek K., Arthur D.C., Herzig G.P., Baer M.R., Schiffer C.A., Heinonen K., Knuutila S., Nousiainen T., Ruutu T., Block A.W., Schulman P., Pedersen-Bjergaard J., Croce C.M., and Bloomfield C.D. Partial tandem duplication of ALL1 as a recurrent molecular defect in acute myeloid leukemia with trisomy 11. Cancer Res. 56 (1996) 1418-1425
34. Caligiuri M.A., Strout M.P., Lawrence D., Arthur D.C., Baer M.R., Yu F., Knuutila S., Mrozek K., Oberkircher A.R., Marcucci G., de la Chapelle A., Elonen E., Block A.W., Rao P.N., Herzig G.P., Powell B.L., Ruutu T., Schiffer C.A., and Bloomfield C.D. Rearrangement of ALL1 (MLL) in acute myeloid leukemia with normal cytogenetics. Cancer Res. 58 (1998) 55-59
35. Felix C.A., Megonigal M.D., Chervinsky D.S., Leonard D.G., Tsuchida N., Kakati S., Block A.M., Fisher J., Grossi M., Salhany K.I., Jani-Sait S.N., and Aplan P.D. Association of germline p53 mutation with MLL segmental jumping translocation in treatment-related leukemia. Blood 91 (1998) 4451-4456
36. Gu Y., Alder H., Nakamura T., Schichman S.A., Prasad R., Canaani O., Saito H., Croce C.M., and Canaani E. Sequence analysis of the breakpoint cluster region in the ALL-1 gene involved in acute leukemia. Cancer Res. 54 (1994) 2326-2330
37. Reichel M., Gillert E., Angermuller S., Hensel J.P., Heidel F., Lode M., Leis T., Biondi A., Haas O.A., Strehl S., Panzer-Grumayer E.R., Griesinger F., Beck J.D., Greil J., Fey G.H., Uckun F.M., and Marschalek R. Biased distribution of chromosomal breakpoints involving the MLL gene in infants versus children and adults with t(4;11) ALL. Oncogene 20 (2001) 2900-2907
38. Gu Y., Cimino G., Alder H., Nakamura T., Prasad R., Canaani O., Moir D.T., Jones C., Nowell P.C., Croce C.M., et al. The (4;11)(q21;q23) chromosome translocations in acute leukemias involve the VDJ recombinase. Proc. Natl. Acad. Sci. U.S.A. 89 (1992) 10464-10468
39. Aplan P.D., Lombardi D.P., Ginsberg A.M., Cossman J., Bertness V.L., and Kirsch I.R. Disruption of the human SCL locus by "illegitimate" V-(D)-J recombinase activity. Science 250 (1990) 1426-1429
40. Tycko B., and Sklar J. Chromosomal translocations in lymphoid neoplasia: a reappraisal of the recombinase model. Cancer Cells 2 (1990) 1-8
41. Kolomietz E., Meyn M.S., Pandita A., and Squire J.A. The role of Alu repeat clusters as mediators of recurrent chromosomal aberrations in tumors. Genes Chromosomes Cancer 35 (2002) 97-112
42. Elliott B., Richardson C., and Jasin M. Chromosomal translocation mechanisms at intronic Alu elements in mammalian cells. Mol. Cell 17 (2005) 885-894
43. Jeffs A.R., Benjes S.M., Smith T.L., Sowerby S.J., and Morris C.M. The Bcr gene recombines preferentially with Alu elements in complex Bcr-Abl translocations of chronic myeloid leukaemia. Hum. Mol. Genet. 7 (1998) 767-776
44. Super H.G., Strissel P.L., Sobulo O.M., Burian D., Reshmi S.C., Roe B., Zeleznik-Le N.J., Diaz M.O., and Rowley J.D. Identification of complex genomic breakpoint junctions in the t(9;11) MLL-AF9 fusion gene in acute leukemia. Genes Chromosomes Cancer 20 (1997) 185-195
45. Strout M.P., Marcucci G., Bloomfield C.D., and Caligiuri M.A. The partial tandem duplication of ALL1 (MLL) is consistently generated by Alu-mediated homologous recombination in acute myeloid leukemia. Proc. Natl. Acad. Sci. U.S.A. 95 (1998) 2390-2395
46. Burden D.A., and Osheroff N. Mechanism of action of eukaryotic topoisomerase II and drugs targeted to the enzyme. Biochim. Biophys. Acta 1400 (1998) 139-154
47. Kas E., and Laemmli U.K. In vivo topoisomerase II cleavage of the Drosophila histone and satellite III repeats: DNA sequence and structural characteristics. EMBO J. 11 (1992) 705-716
48. Felix C.A., Lange B.J., Hosler M.R., Fertala J., and Bjornsti M.A. Chromosome band 11q23 translocation breakpoints are DNA topoisomerase II cleavage sites. Cancer Res. 55 (1995) 4287-4292
49. Zhou R.H., Wang P., Zou Y., Jackson-Cook C.K., and Povirk L.F. A precise interchromosomal reciprocal exchange between hot spots for cleavable complex formation by topoisomerase II in amsacrine-treated Chinese hamster ovary cells. Cancer Res. 57 (1997) 4699-4702
50. Bae Ys., Kawasaki I., Ikeda H., and Liu Lf. Illegitimate recombination mediated by calf thymus DNA topoisomerase II in vitro. Proc. Natl. Acad. Sci. U.S.A. 85 (1988) 2076-2080
51. Ahuja H.G., Felix C.A., and Aplan P.D. Potential role for DNA topoisomerase II poisons in the generation of t(11;20)(p15;q11) translocations. Genes Chromosomes Cancer 29 (2000) 96-105
52. Whitmarsh R.J., Saginario C., Zhuo Y., Hilgenfeld E., Rappaport E.F., Megonigal M.D., Carroll M., Liu M., Osheroff N., Cheung N.K., Slater D.J., Ried T., Knutsen T., Blair I.A., and Felix C.A. Reciprocal DNA topoisomerase II cleavage events at 5′-TATTA-3′ sequences in MLL and AF-9 create homologous single-stranded overhangs that anneal to form der(11) and der(9) genomic breakpoint junctions in treatment-related AML without further processing. Oncogene 22 (2003) 8448-8459
53. Langer T., Metzler M., Reinhardt D., Viehmann S., Borkhardt A., Reichel M., Stanulla M., Schrappe M., Creutzig U., Ritter J., Leis T., Jacobs U., Harbott J., Beck J.D., Rascher W., and Repp R. Analysis of t(9;11) chromosomal breakpoint sequences in childhood acute leukemia: almost identical MLL breakpoints in therapy-related AML after treatment without etoposides. Genes Chromosomes Cancer 36 (2003) 393-401
54. Allan J.M., Wild C.P., Rollinson S., Willett E.V., Moorman A.V., Dovey G.J., Roddam P.L., Roman E., Cartwright R.A., and Morgan G.J. Polymorphism in glutathione S-transferase P1 is associated with susceptibility to chemotherapy-induced leukemia. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 11592-11597
55. Reichel M., Gillert E., Nilson I., Siegler G., Greil J., Fey G.H., and Marschalek R. Fine structure of translocation breakpoints in leukemic blasts with chromosomal translocation t(4;11): the DNA damage-repair model of translocation. Oncogene 17 (1998) 3035-3044
56. Broeker P.L., Super H.G., Thirman M.J., Pomykala H., Yonebayashi Y., Tanabe S., Zeleznik-Le N., and Rowley J.D. Distribution of 11q23 breakpoints within the MLL breakpoint cluster region in de novo acute leukemia and in treatment-related acute myeloid leukemia: correlation with scaffold attachment regions and topoisomerase II consensus binding sites. Blood 87 (1996) 1912-1922
57. Aplan P.D., Chervinsky D.S., Stanulla M., and Burhans W.C. Site-specific DNA cleavage within the MLL breakpoint cluster region induced by topoisomerase II inhibitors. Blood 87 (1996) 2649-2658
58. Stanulla M., Wang J., Chervinsky D.S., Thandla S., and Aplan P.D. DNA cleavage within the MLL breakpoint cluster region is a specific event which occurs as part of higher-order chromatin fragmentation during the initial stages of apoptosis. Mol. Cell. Biol. 17 (1997) 4070-4079
59. Strissel P.L., Strick R., Rowley J.D., and Zeleznik-Le N.J. An in vivo topoisomerase II cleavage site and a DNase I hypersensitive site colocalize near exon 9 in the MLL breakpoint cluster region. Blood 92 (1998) 3793-3803
60. Oberhammer F., Wilson J.W., Dive C., Morris I.D., Hickman J.A., Wakeling A.E., Walker P.R., and Sikorska M. Apoptotic death in epithelial cells: cleavage of DNA to 300 and/or 50 kb fragments prior to or in the absence of internucleosomal fragmentation. EMBO J. 12 (1993) 3679-3684
61. Razin S.V., Gromova I.I., and Iarovaia O.V. Specificity and functional significance of DNA interaction with the nuclear matrix: new approaches to clarify the old questions. Int. Rev. Cytol. 162B (1995) (review, 142 refs)
62. Bortner C.D., Oldenburg N.B.E., and Cidlowski J.A. The role of DNA fragmentation in apoptosis. Trends Cell Biol. 5 (1995) 21-26
63. Bode J., Schlake T., Rios-Ramirez M., Mielke C., Stengert M., Kay V., and Klehr-Wirth D. Scaffold/matrix-attached regions: structural properties creating transcriptionally active loci. Int. Rev. Cytol. 162A (1995) 389-454
64. Stanulla M., Chhalliyil P., Wang J., Jani-Sait S.N., and Aplan P.D. Mechanisms of MLL gene rearrangement: site-specific DNA cleavage within the breakpoint cluster region is independent of chromosomal context. Hum. Mol. Genet. 10 (2001) 2481-2491
65. Bode J., Benham C., Ernst E., Knopp A., Marschalek R., Strick R., and Strissel P. Fatal connections: when DNA ends meet on the nuclear matrix. J. Cell. Biochem. Suppl. 35 (2000) 3-22
66. Vaughan A.T., Betti C.J., and Villalobos M.J. Surviving apoptosis. Apoptosis 7 (2002) 173-177
67. Hoeppner D.J., Hengartner M.O., and Schnabel R. Engulfment genes cooperate with ced-3 to promote cell death in Caenorhabditis elegans. Nature 412 (2001) 202-206
68. Green D.R., and Beere H.M. Apoptosis. Mostly dead. Nature 412 (2001) 133-135
69. Reddien P.W., Cameron S., and Horvitz H.R. Phagocytosis promotes programmed cell death in C. elegans. Nature 412 (2001) 198-202
70. Betti C.J., Villalobos M.J., Diaz M.O., and Vaughan A.T. Apoptotic stimuli initiate MLL-AF9 translocations that are transcribed in cells capable of division. Cancer Res. 63 (2003) 1377-1381
71. Libura J., Slater D.J., Felix C.A., and Richardson C. Therapy-related acute myeloid leukemia-like MLL rearrangements are induced by etoposide in primary human CD34+ cells and remain stable after clonal expansion. Blood 105 (2005) 2124-2131